Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PALISADE BIO, INC.

(PALI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Palisade Bio : Secures $5.2 Million Investment From Yuma Regional Medical Center; Shares Advance

08/20/2021 | 09:49am EDT


© MT Newswires 2021
All news about PALISADE BIO, INC.
09/13PALISADE BIO, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K..
AQ
09/09PALISADE BIO : to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Con..
AQ
08/31PALISADE BIO : Maxim Starts Palisade Bio at Buy With $7 Price Target
MT
08/24Palisade Bio Reports Second Quarter Financial Results and Provides Business Update
GL
08/24Palisade Bio, Inc. Announces Unaudited Earnings Results for the Second Quarter and Six ..
CI
08/24PALISADE BIO : Entry into a Definitive Material Agreement (Form 8-K)
PU
08/24PALISADE BIO, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equi..
AQ
08/23PALISADE BIO : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF ..
AQ
08/20PALISADE BIO : Secures $5.2 Million Investment From Yuma Regional Medical Center; Shares A..
MT
08/20PALISADE BIO : Announces $5.2M Investment by the Yuma Regional Medical Center
AQ
More news
Analyst Recommendations on PALISADE BIO, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -42,7 M - -
Net Debt 2021 - - -
P/E ratio 2021 -0,60x
Yield 2021 -
Capitalization 36,2 M 36,2 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 10
Free-Float 63,8%
Chart PALISADE BIO, INC.
Duration : Period :
Palisade Bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PALISADE BIO, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 2,80 $
Average target price 7,00 $
Spread / Average Target 150%
EPS Revisions
Managers and Directors
Thomas M. Hallam Chief Executive Officer & Director
J. D. Finley Chief Financial Officer
Ryker Willie Finance Director & Controller
James R. Neal Chairman
John Rodenrys Chief Technology Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
PALISADE BIO, INC.-47.92%36
MODERNA, INC.225.04%134 418
LONZA GROUP AG29.18%59 339
IQVIA HOLDINGS INC.42.23%48 194
SEAGEN INC.-0.71%31 811
CELLTRION, INC.-39.42%25 446